109 related articles for article (PubMed ID: 28258914)
1. Gene expression profiling of circulating CD133
Zekri AN; El-Sisi ER; Abdallah ZF; Ismail A; Barakat Barakat A
J Egypt Natl Canc Inst; 2017 Mar; 29(1):19-24. PubMed ID: 28258914
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
Zekri AN; El-Sisi ER; Youssef ASE; Kamel MM; Nassar A; Ahmed OS; El Kassas M; Barakat AB; Abd El-Motaleb AI; Bahnassy AA
PLoS One; 2018; 13(3):e0193709. PubMed ID: 29534065
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
4. CD133
Liu K; Hao M; Ouyang Y; Zheng J; Chen D
Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312
[TBL] [Abstract][Full Text] [Related]
5. Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report.
Toshima T; Yoshizumi T; Uchiyama H; Ikegami T; Soejima Y; Ikeda T; Kawanaka H; Yamashita Y; Morita M; Oki E; Mimori K; Sugimachi K; Saeki H; Watanabe M; Shirabe K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):383-8. PubMed ID: 24511670
[TBL] [Abstract][Full Text] [Related]
6. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
7. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma.
Yu H; Zhu X; Lin H; Pan H; Zhao F; Zhu M; Sun L; Chai W; Yao M; Yan M
Aging (Albany NY); 2020 Jun; 12(12):12234-12250. PubMed ID: 32564007
[TBL] [Abstract][Full Text] [Related]
8. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
10. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α.
Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK
Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
[TBL] [Abstract][Full Text] [Related]
13. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
14. Bicluster and pathway enrichment analysis of HCV-induced cirrhosis and hepatocellular carcinoma.
Cheng P; Cheng Y; Su MX; Li D; Zhao GZ; Gao H; Li Y; Zhu JY; Li H; Zhang T
Asian Pac J Cancer Prev; 2012; 13(8):3741-5. PubMed ID: 23098464
[TBL] [Abstract][Full Text] [Related]
15. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
[TBL] [Abstract][Full Text] [Related]
16. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.
Zhang L; Zhang L; Li H; Ge C; Zhao F; Tian H; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Sci Rep; 2016 Jun; 6():27426. PubMed ID: 27255419
[TBL] [Abstract][Full Text] [Related]
17. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
19. Incomplete radiofrequency ablation promotes the development of CD133
Yuan CW; Wang ZC; Liu K; Liu DJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models.
Zhao Q; Zhou H; Liu Q; Cao Y; Wang G; Hu A; Ruan L; Wang S; Bo Q; Chen W; Hu C; Xu D; Tao F; Cao J; Ge Y; Yu Z; Li L; Wang H
Oncotarget; 2016 Jul; 7(30):47431-47443. PubMed ID: 27329727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
